BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 10213229)

  • 1. Comparison of activation of CPT-11 by rabbit and human carboxylesterases for use in enzyme/prodrug therapy.
    Danks MK; Morton CL; Krull EJ; Cheshire PJ; Richmond LB; Naeve CW; Pawlik CA; Houghton PJ; Potter PM
    Clin Cancer Res; 1999 Apr; 5(4):917-24. PubMed ID: 10213229
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overexpression of a rabbit liver carboxylesterase sensitizes human tumor cells to CPT-11.
    Danks MK; Morton CL; Pawlik CA; Potter PM
    Cancer Res; 1998 Jan; 58(1):20-2. PubMed ID: 9426050
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An improved human carboxylesterase for enzyme/prodrug therapy with CPT-11.
    Wierdl M; Tsurkan L; Hyatt JL; Edwards CC; Hatfield MJ; Morton CL; Houghton PJ; Danks MK; Redinbo MR; Potter PM
    Cancer Gene Ther; 2008 Mar; 15(3):183-92. PubMed ID: 18188187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo human carboxylesterase cDNA gene transfer to activate the prodrug CPT-11 for local treatment of solid tumors.
    Kojima A; Hackett NR; Ohwada A; Crystal RG
    J Clin Invest; 1998 Apr; 101(8):1789-96. PubMed ID: 9541511
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sensitization of human tumor cells to CPT-11 via adenoviral-mediated delivery of a rabbit liver carboxylesterase.
    Wierdl M; Morton CL; Weeks JK; Danks MK; Harris LC; Potter PM
    Cancer Res; 2001 Jul; 61(13):5078-82. PubMed ID: 11431344
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural constraints affect the metabolism of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) by carboxylesterases.
    Wadkins RM; Morton CL; Weeks JK; Oliver L; Wierdl M; Danks MK; Potter PM
    Mol Pharmacol; 2001 Aug; 60(2):355-62. PubMed ID: 11455023
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conversion of the CPT-11 metabolite APC to SN-38 by rabbit liver carboxylesterase.
    Guichard SM; Morton CL; Krull EJ; Stewart CF; Danks MK; Potter PM
    Clin Cancer Res; 1998 Dec; 4(12):3089-94. PubMed ID: 9865925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Isolation and partial characterization of a cDNA encoding a rabbit liver carboxylesterase that activates the prodrug irinotecan (CPT-11).
    Potter PM; Pawlik CA; Morton CL; Naeve CW; Danks MK
    Cancer Res; 1998 Jun; 58(12):2646-51. PubMed ID: 9635592
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Secreted and tumour targeted human carboxylesterase for activation of irinotecan.
    Oosterhoff D; Pinedo HM; van der Meulen IH; de Graaf M; Sone T; Kruyt FA; van Beusechem VW; Haisma HJ; Gerritsen WR
    Br J Cancer; 2002 Sep; 87(6):659-64. PubMed ID: 12237777
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification and activities of human carboxylesterases for the activation of CPT-11, a clinically approved anticancer drug.
    Senter PD; Beam KS; Mixan B; Wahl AF
    Bioconjug Chem; 2001; 12(6):1074-80. PubMed ID: 11716702
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against human tumor xenografts: lack of cross-resistance in vivo in tumors with acquired resistance to the topoisomerase I inhibitor 9-dimethylaminomethyl-10-hydroxycamptothecin.
    Houghton PJ; Cheshire PJ; Hallman JC; Bissery MC; Mathieu-Boué A; Houghton JA
    Cancer Res; 1993 Jun; 53(12):2823-9. PubMed ID: 8504425
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural insights into CPT-11 activation by mammalian carboxylesterases.
    Bencharit S; Morton CL; Howard-Williams EL; Danks MK; Potter PM; Redinbo MR
    Nat Struct Biol; 2002 May; 9(5):337-42. PubMed ID: 11967565
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of CPT-11 hydrolysis by human liver carboxylesterase isoforms hCE-1 and hCE-2.
    Humerickhouse R; Lohrbach K; Li L; Bosron WF; Dolan ME
    Cancer Res; 2000 Mar; 60(5):1189-92. PubMed ID: 10728672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enzyme-prodrug systems: carboxylesterase/CPT-11.
    Danks MK; Potter PM
    Methods Mol Med; 2004; 90():247-62. PubMed ID: 14657567
    [No Abstract]   [Full Text] [Related]  

  • 15. Hydrolysis of irinotecan and its oxidative metabolites, 7-ethyl-10-[4-N-(5-aminopentanoic acid)-1-piperidino] carbonyloxycamptothecin and 7-ethyl-10-[4-(1-piperidino)-1-amino]-carbonyloxycamptothecin, by human carboxylesterases CES1A1, CES2, and a newly expressed carboxylesterase isoenzyme, CES3.
    Sanghani SP; Quinney SK; Fredenburg TB; Davis WI; Murry DJ; Bosron WF
    Drug Metab Dispos; 2004 May; 32(5):505-11. PubMed ID: 15100172
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proficient metabolism of irinotecan by a human intestinal carboxylesterase.
    Khanna R; Morton CL; Danks MK; Potter PM
    Cancer Res; 2000 Sep; 60(17):4725-8. PubMed ID: 10987276
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of rat serum carboxylesterase in the activation of paclitaxel and camptothecin prodrugs.
    Senter PD; Marquardt H; Thomas BA; Hammock BD; Frank IS; Svensson HP
    Cancer Res; 1996 Apr; 56(7):1471-4. PubMed ID: 8603386
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A virus-directed enzyme prodrug therapy approach to purging neuroblastoma cells from hematopoietic cells using adenovirus encoding rabbit carboxylesterase and CPT-11.
    Meck MM; Wierdl M; Wagner LM; Burger RA; Guichard SM; Krull EJ; Harris LC; Potter PM; Danks MK
    Cancer Res; 2001 Jul; 61(13):5083-9. PubMed ID: 11431345
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mouse liver and kidney carboxylesterase (M-LK) rapidly hydrolyzes antitumor prodrug irinotecan and the N-terminal three quarter sequence determines substrate selectivity.
    Xie M; Yang D; Wu M; Xue B; Yan B
    Drug Metab Dispos; 2003 Jan; 31(1):21-7. PubMed ID: 12485949
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation of a camptothecin prodrug by specific carboxylesterases as predicted by quantitative structure-activity relationship and molecular docking studies.
    Yoon KJ; Krull EJ; Morton CL; Bornmann WG; Lee RE; Potter PM; Danks MK
    Mol Cancer Ther; 2003 Nov; 2(11):1171-81. PubMed ID: 14617791
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.